Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libertal for Smoking Cessation
NCT00317213Phase 2Completed
- Sponsor
- Kaplan Medical Center
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Libertal in nicotine dependence (5 arms), sponsored by Kaplan Medical Center. Primary endpoints: Quit Smoking Rates at 28 days and Safety. Started Feb 2002; status: completed.
02
Drugs
Libertal
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00317213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317213.